CL2021001446A1 - Anticuerpo humanizado anti-receptor de igf-i - Google Patents

Anticuerpo humanizado anti-receptor de igf-i

Info

Publication number
CL2021001446A1
CL2021001446A1 CL2021001446A CL2021001446A CL2021001446A1 CL 2021001446 A1 CL2021001446 A1 CL 2021001446A1 CL 2021001446 A CL2021001446 A CL 2021001446A CL 2021001446 A CL2021001446 A CL 2021001446A CL 2021001446 A1 CL2021001446 A1 CL 2021001446A1
Authority
CL
Chile
Prior art keywords
igf
receptor
humanized anti
receptor antibody
antibody
Prior art date
Application number
CL2021001446A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Akira Tanokura
Kenichiro Takagi
Hirotsugu Kato
Satoshi Yamamura
Naoko Namiki
Daisuke Ishikawa
Hirofumi Higuchi
Tomoyo Takeo
Masayo Ohori
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CL2021001446A1 publication Critical patent/CL2021001446A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona un anticuerpo humanizado que aumenta la masa muscular por medio del receptor de IGF-I mientras que no disminuye el nivel de glucosa en sangre. Un anticuerpo humanizado anti-receptor de IGF-I o su fragmento o un derivado del mismo comprende secuencias de aminoácidos específicas, tales como SEQ ID NOs: 1 a 6 como cada secuencia de CDR, y puede unirse específicamente al dominio extracelular de un receptor de IGF-I.
CL2021001446A 2018-12-03 2021-06-02 Anticuerpo humanizado anti-receptor de igf-i CL2021001446A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018226669 2018-12-03

Publications (1)

Publication Number Publication Date
CL2021001446A1 true CL2021001446A1 (es) 2022-01-14

Family

ID=70974206

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001446A CL2021001446A1 (es) 2018-12-03 2021-06-02 Anticuerpo humanizado anti-receptor de igf-i

Country Status (19)

Country Link
US (1) US20220033485A1 (es)
EP (1) EP3895732A4 (es)
JP (2) JP7246409B2 (es)
KR (1) KR20210088625A (es)
CN (1) CN113286612A (es)
AR (1) AR117673A1 (es)
AU (1) AU2019393487A1 (es)
BR (1) BR112021010479A2 (es)
CA (1) CA3120740A1 (es)
CL (1) CL2021001446A1 (es)
CO (1) CO2021007229A2 (es)
IL (1) IL283099A (es)
MA (1) MA54464A (es)
MX (1) MX2021006495A (es)
PH (1) PH12021551210A1 (es)
SG (1) SG11202105714UA (es)
TW (1) TW202039559A (es)
WO (1) WO2020116398A1 (es)
ZA (1) ZA202103350B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021282629A1 (en) * 2020-06-02 2022-12-01 Teijin Pharma Limited Anti-IGF-1 receptor humanized antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1399483E (pt) * 2001-01-05 2010-07-20 Pfizer Anticorpos contra o receptor do factor i de crescimento tipo insulina
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2009231394B2 (en) 2008-04-03 2013-09-05 F. Hoffmann-La Roche Ag Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders
JP6096267B1 (ja) 2015-12-09 2017-03-15 上銀科技股▲分▼有限公司 ボールねじに用いる防塵ユニット
AR112600A1 (es) * 2017-05-30 2019-11-20 Teijin Pharma Ltd Anticuerpo anti-receptor de igf-i

Also Published As

Publication number Publication date
PH12021551210A1 (en) 2021-11-08
KR20210088625A (ko) 2021-07-14
EP3895732A4 (en) 2022-09-14
SG11202105714UA (en) 2021-06-29
CA3120740A1 (en) 2020-06-11
JPWO2020116398A1 (ja) 2021-09-30
MX2021006495A (es) 2021-07-06
JP7246409B2 (ja) 2023-03-27
WO2020116398A1 (ja) 2020-06-11
MA54464A (fr) 2021-10-20
JP2023011808A (ja) 2023-01-24
BR112021010479A2 (pt) 2021-11-16
CN113286612A (zh) 2021-08-20
CO2021007229A2 (es) 2021-08-19
EP3895732A1 (en) 2021-10-20
AU2019393487A1 (en) 2021-06-03
AR117673A1 (es) 2021-08-25
IL283099A (en) 2021-06-30
TW202039559A (zh) 2020-11-01
US20220033485A1 (en) 2022-02-03
ZA202103350B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
PE20190201A1 (es) Receptores quimericos de flt3 y metodos de uso de los mismos
RS53750B1 (en) NOTCH1 RECEPTOR BINDING AGENTS AND APPLICATION PROCEDURES
TR201904088T4 (tr) Anti-CGRP bileşimleri ve bunların kullanımları.
PE20121703A1 (es) Polipeptidos agonistas que se enlazan a dr5
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CR10736A (es) Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon
NZ610734A (en) Human antibodies to the glucagon receptor
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20200734A1 (es) Anticuerpos anti-tgf-beta y su uso
PE20081546A1 (es) Antagonistas del dr6
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
CL2021001446A1 (es) Anticuerpo humanizado anti-receptor de igf-i
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
PH12019502704A1 (en) Anti-igf-i receptor antibody
AR073459A1 (es) Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
EA201201113A1 (ru) Способы и соединения для роста мышц
MX2021001592A (es) Nuevas construcciones de car que comprenden dominios de tnfr2.
MX2021006457A (es) Anticuerpo inhibidor para usarse para tratar la resistencia severa a la insulina.
RU2019126152A (ru) Однодоменные антитела, направленные против внутриклеточных антигенов
ES2570182T3 (es) Prevención y tratamiento de la enfermedad sinucleinopática y amiloidogénica
MX2021012160A (es) Anticuerpos antiintegrina y usos de los mismos.
CL2022003399A1 (es) Anticuerpo humanizado anti- receptor de igf-1